Age (years)
|
−0.07
|
0.05
|
0.09
|
−0.09
|
−0.29
*
|
BMI (kg/m2)
|
0.24
|
−0.05
|
−0.23
|
−0.10
|
−0.25
|
Disease activity (DAS28)
|
0.23
|
0.30
*
|
0.14
|
0.35
*
|
−0.01
|
Disability (HAQ-DI)
|
0.33
*
|
0.19
|
0.09
|
0.33
*
|
0.12
|
Pain (VAS)
|
0.15
|
0.17
|
0.29
*
|
0.39
*
|
0.47
*
|
Prednisone use (yes = 1)
|
0.14
|
−0.05
|
0.00
|
0.01
|
−0.01
|
DMARD use (yes = 1)
|
−0.04
|
−0.07
|
−0.30
|
0.21
|
0.08
|
Biologic use (yes = 1)
|
−0.25
|
−0.37
*
|
0.21
|
−0.33
*
|
0.01
|
Comorbidity index
|
0.17
|
0.12
|
0.17
|
0.26
|
−0.08
|
Plasma hsCRP (mg/L)
|
0.20
|
0.07
|
0.11
|
−0.03
|
−0.17
|
Plasma IL-1β (pg/mL)
|
0.01
|
−0.07
|
−0.07
|
−0.14
|
−0.12
|
Plasma IL-6 (pg/mL)
|
−0.03
|
0.11
|
0.12
|
−0.01
|
−0.10
|
Plasma IL-8 (pg/mL)
|
−0.11
|
0.06
|
0.11
|
0.14
|
0.02
|
Plasma TNF-α (pg/mL)
|
−0.37
*
|
−0.15
|
0.02
|
−0.23
|
−0.08
|
Plasma IL-18 (pg/mL)
|
−0.08
|
−0.12
|
−0.02
|
−0.24
|
0.06
|
GlycA (μmol/L)
|
0.41
*
|
0.38
*
|
−0.06
|
0.07
|
−0.21
|
HOMA
|
0.11
|
0.04
|
−0.06
|
−0.10
|
−0.07
|
Insulin sensitivity (10-5.min-1/(pmol/L))
|
−0.20
|
−0.19
|
−0.06
|
−0.09
|
−0.18
|
Fasting insulin (mU/L)
|
0.13
|
0.09
|
−0.13
|
−0.06
|
−0.06
|
Visceral adiposity (cm2)
|
0.11
|
0.01
|
−0.28
|
0.03
|
−0.23
|
Abdominal subcutaneous adiposity (cm2)
|
0.21
|
0.06
|
−0.19
|
−0.06
|
−0.19
|
Total abdominal adiposity (cm2)
|
0.19
|
0.07
|
−0.24
|
−0.06
|
−0.28
|
Thigh muscle density (Hu)
|
−0.04
|
−0.10
|
0.06
|
0.16
|
0.28
*
|
Thigh inter-muscular adiposity (cm2)
|
0.12
|
0.01
|
−0.08
|
−0.11
|
−0.12
|
Thigh subcutaneous adiposity (cm2)
|
0.31
*
|
−0.07
|
−0.11
|
−0.09
|
−0.11
|
Exercise (min/day)
|
−0.40
*
|
−0.38
*
|
−0.05
|
−0.38
*
|
−0.11
|
Physical activity (MET h/day)
|
−0.33
*
|
−0.26
|
0.10
|
−0.35
*
|
−0.15
|